G-Precision trial (G-Precision trial)

Recruiting

• Conditions: Pancreatic Cancer

• Registration Number: jRCT1032230578

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2024-01-19
• Study Start: 2024-03-15
• Last Update Posted: 2024-05-29

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

1. Patients with unresectable advanced or recurrent pancreatic cancer diagnosed by pathological or imaging findings
2. Patients who are scheduled to undergo EUS-TA
3. Patients who are scheduled to undergo CGP examination using EUS-TA specimen at the time of completion or expected completion of standard treatment.
4. 18 years of age or older
5. Patients who are expected to survive more than 3 months.
6. Patients who have been fully informed about the study, understand it, and give written consent of their own free will.

Exclusion Criteria

1. Patients with resectable pancreatic cancer or borderline resectable pancreatic cancer who are scheduled for surgery in the future
2. Patients with performance status 3-4
3. Patients who have difficulty in receiving anti-tumor therapy
4. Patients with bleeding tendency (platelets <50,000/mm3, PT <70%) (however, patients who recover with blood transfusion or vitamin K administration may be enrolled)
5. Patients at high risk of thromboembolism due to withdrawal of antithrombotic drugs and for whom withdrawal or replacement of antithrombotic drugs based on the "Guidelines for Gastrointestinal Endoscopy for Patients Taking Antithrombotic Drugs" is not possible.
6. Patients with heart failure (NYHA classification III-IV) or respiratory failure (PaO2 < 60 Torr)
7. Patients who are pregnant or may become pregnant
8. Other cases that the principal investigator determines to be inappropriate as a research subject.

Study & Design

• Study Type: Interventional
• Study Design: parallel assignment

Primary Outcome Measures

Name	Time	Method
-		The success rate of CGP testing